VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2021 | ASCO GU 2021 highlights: enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617

Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, shares her highlights from ASCO GU 2021, in particular discussing the promising results seen with studies of the antibody-drug conjugate enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617 versus cabazitaxel. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Alison Birtle, MRCP, FRCR, MD, has received research support from Sanofi Aventis, and has participated in advisory boards or provided educational support to Janssen, Astellas, Bayer, Roche, BMS, Pfizer, Sanofi Aventis and MSD.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter